BR0214020A - Método para tratar fibrose cìstica - Google Patents

Método para tratar fibrose cìstica

Info

Publication number
BR0214020A
BR0214020A BR0214020-9A BR0214020A BR0214020A BR 0214020 A BR0214020 A BR 0214020A BR 0214020 A BR0214020 A BR 0214020A BR 0214020 A BR0214020 A BR 0214020A
Authority
BR
Brazil
Prior art keywords
cystic fibrosis
treat cystic
fibrosis
treating
treat
Prior art date
Application number
BR0214020-9A
Other languages
English (en)
Inventor
Linda S Higgins
David Y Liu
Andrew A Protter
Original Assignee
Scios Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Inc filed Critical Scios Inc
Publication of BR0214020A publication Critical patent/BR0214020A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"MéTODO PARA TRATAR FIBROSE CìSTICA". A presente invenção refere-se a métodos para tratar fibrose cística, administrando certos derivados de imidazol.
BR0214020-9A 2001-11-09 2002-11-08 Método para tratar fibrose cìstica BR0214020A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33820901P 2001-11-09 2001-11-09
PCT/US2002/035939 WO2003041644A2 (en) 2001-11-09 2002-11-08 Method to treat cystic fibrosis

Publications (1)

Publication Number Publication Date
BR0214020A true BR0214020A (pt) 2004-10-13

Family

ID=23323870

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214020-9A BR0214020A (pt) 2001-11-09 2002-11-08 Método para tratar fibrose cìstica

Country Status (9)

Country Link
US (1) US20040009990A1 (pt)
EP (1) EP1453515A4 (pt)
JP (1) JP2005511616A (pt)
BR (1) BR0214020A (pt)
CA (1) CA2466665A1 (pt)
IL (1) IL161667A0 (pt)
PL (1) PL369019A1 (pt)
TR (1) TR200401028T2 (pt)
WO (1) WO2003041644A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003224025A1 (en) * 2002-04-05 2003-10-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg p38 kinase inhibitors for treating mucus hypersecretion
US20060100432A1 (en) 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
JP5385605B2 (ja) * 2005-03-11 2014-01-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのモジュレーター
KR20080064971A (ko) 2005-10-06 2008-07-10 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ-결합 카세트 전달체의 조절자
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
WO2007084841A2 (en) * 2006-01-13 2007-07-26 Wyeth Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US8884020B2 (en) * 2006-08-07 2014-11-11 Ironwood Pharmaceuticals, Inc. Indole compounds
MX336731B (es) 2010-01-28 2016-01-28 Harvard College Composiciones y metodos para potenciar la actividad de proteasoma.
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
DK2707101T3 (da) 2011-05-12 2019-05-13 Proteostasis Therapeutics Inc Proteostaseregulatorer
EP2771001A4 (en) 2011-10-25 2015-03-25 Merck Sharp & Dohme PIPERIDINYL-alkyne-orexin
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028292A1 (en) * 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6340685B1 (en) * 1998-05-22 2002-01-22 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
ATE316961T1 (de) * 1998-05-22 2006-02-15 Scios Inc Heterozyclische derivate für die behandlung von herzversagen und andere erkrankungen
JP2003500403A (ja) * 1999-05-21 2003-01-07 サイオス，インコーポレーテッド ｐ３８キナーゼのインヒビターとしてのインドール型誘導体

Also Published As

Publication number Publication date
CA2466665A1 (en) 2003-05-22
WO2003041644A2 (en) 2003-05-22
JP2005511616A (ja) 2005-04-28
IL161667A0 (en) 2004-09-27
PL369019A1 (en) 2005-04-18
WO2003041644A3 (en) 2003-11-13
TR200401028T2 (tr) 2004-11-22
EP1453515A4 (en) 2006-11-29
US20040009990A1 (en) 2004-01-15
EP1453515A2 (en) 2004-09-08

Similar Documents

Publication Publication Date Title
BR0214020A (pt) Método para tratar fibrose cìstica
BR0114054A (pt) Método para tratar alergias usando pirazóis substituìdos
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
PT1143967E (pt) Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas
IL157254A0 (en) N-substituted nonaryl-heterocyclic nmda/mr2b antagonists
DK1355889T3 (da) Substituerede triazoldiaminderivater som kinaseinhibitorer
ID28024A (id) Metode bagi produksi 1,3-propanadiol oleh organisme-organisme rekombinan yang mengandung ge-gen untuk pengakutan vitamin b12
PT1333887E (pt) Metodo de tratamento de desordens musculares
WO2004098494A3 (en) Compounds, compositions, and methods
BR9610838A (pt) Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização.
GB0019283D0 (en) Organic compounds
WO2004047673A3 (en) Treatment of liver disease with active vitamin d compounds
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
AU3831301A (en) Method for treating ocular pain
AP1729A (en) Single dose azithromycin for treating respiratory infections.
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
MXPA03006607A (es) Metodo combinado para tratar trastornos dependientes de hormonas.
BRPI0415678A (pt) compostos de pirimidina para o tratamento de inflamação
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
ZA200609220B (en) Method of treating dry eye disorders and uveitis
NO20003785D0 (no) Anvendelse av 2-amino-6-trifluormetoksy-benzotiazol for prevensjon eller terapi av cerebellum dysfunksjon
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
MX9604692A (es) Derivados de quinoxalina para el tratamiento de tinnitus.
DK1553938T3 (da) Anvendelse af epothilonderivater til behandling af hyperparathyroidisme

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]